

**What is claimed is:**

- Sub  
Q2
1. An aerosol container for pharmaceutically active aerosols that are to be administered in predetermined amounts and that are supplied in the container in the form of a suspension, the suspension also comprising, in addition to a pharmaceutically active substance, at least a propellant gas, which aerosol container has a metering valve that comprises a metering chamber and a valve stem, the metering chamber being in communication with the interior of the container and being full of a predetermined amount of the aerosol in a first position of the valve stem, and releasing the amount of aerosol disposed in the metering chamber in a second position of the valve stem, wherein the propellant gas is an alternative propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons and, where appropriate, also cosolvents and/or surfactants, and wherein the inner wall of the container is coated with a plastics coating.
  2. An aerosol container according to claim 1, wherein the plastics coating disposed on the inner wall of the container is of polytetrafluoroethylene or perfluoroethylenepropylene.
  3. An aerosol container according to claim 1, wherein the thickness of the container wall is in the range from approximately 0.1 mm to approximately 2 mm, and is especially approximately 0.4 mm, and the thickness of the plastics coating is in the range from approximately 1 nm to approximately 1  $\mu$ m, and is especially some 10 nm.
  - Sub  
C1  
Sub  
Q3
  4. An aerosol container according to claim 1, wherein the volume of the interior of the container is in the range from approximately 1 ml to approximately 100 ml and the volume of the metering chamber is from approximately 5  $\mu$ l to approximately 400  $\mu$ l.
  5. Method for the storage and administration of a predetermined amount of a pharmaceutically active aerosol in the form of a suspension, the suspension also comprising, in addition to a pharmaceutically active substance, at least an alternative propellant gas that is free of fluorochlorohydrocarbons, preferably a propellant gas that comprises only fluorohydrocarbons and, where appropriate, also cosolvents and/or surfactants, wherein a container according to claim 1 is used.
  6. Method according to claim 5, wherein the pharmaceutically active substance in the suspension used is an anti-asthmatically active substance or substance mixture.
- 8

7. Method according to claim 6, wherein the pharmaceutically active substance in the suspension used is Formoterol or a corticosteroid, especially 9 $\alpha$ -chloro-6 $\alpha$ -fluoro-11 $\beta$ ,17 $\alpha$ -dihydroxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-diene-17 $\beta$ -methoxycarbonyl-17-propionate, or a mixture of Formoterol and that corticosteroid.

8. Method according to claim 6, wherein the pharmaceutically active substance used is (1R,2S)-(3E,5Z)-7-[1-(3-trifluoromethylphenyl)-1-hydroxy-10-(4-acetyl-3-hydroxy-2-propylphenoxy)-3,5-decadien-2-ylthio]-4-oxo-4H-1-benzopyrane-2-carboxylic acid.

add BT  
add  
ad 1